Kalasekhar, VS (2020) Favorable outcomes and reduced toxicity with a novel vinblastine-based non-high dose methotrexate (HDMTX) regimen (modified MCP-842) in pediatric anaplastic large cell lymphoma (ALCL): experience from India. Leukemia & Lymphoma, 61 (4). pp. 912-918. ISSN 1029-2403
![]() |
PDF
9186 DisplayPdf.pdf - Published Version Restricted to Registered users only Download (1MB) | Request a copy |
Abstract
Anaplastic large cell lymphoma (ALCL) is a rare form of non-Hodgkin lymphoma (NHL) in children. Most treatment regimens include high-dose methotrexate (HDMTX), which is logistically difficult to administer in resource-limited settings. We evaluated the outcomes of pediatric ALCL patients treated on a uniform protocol (Modified Multicentric Protocol, MCP-842 regimen) at our hospital between January 2005 and December 2016. Of the 68 patients who received treatment on the Modified MCP842 protocol, 46 patients are alive in remission, 11(16%) had disease progression, 9(13%) relapsed after achieving remission, and 5(7%) had treatment-related mortality (TRM). Seventeen of 20 relapsed/progressed patients subsequently expired. With a median follow-up of 55 months (range 2–165 months), the 4-year event-free survival (EFS) and overall survival (OS) are 63% (95% CI of 50–73%) and 70%(95% CI of 57–79%), respectively. An indigenous protocol using vinblastine (without HDMTX and steroids) is feasible in a resource-limited setting and achieves outcomes comparable to regimens incorporating HDMTX, with lower toxicity
Item Type: | Article |
---|---|
Uncontrolled Keywords: | Pediatric ALCL; outcomes; vinblastine |
Subjects: | Medicine > KMC Manipal > Medical Oncology |
Depositing User: | KMC Library |
Date Deposited: | 03 Aug 2020 08:50 |
Last Modified: | 03 Aug 2020 08:50 |
URI: | http://eprints.manipal.edu/id/eprint/155476 |
Actions (login required)
![]() |
View Item |